Research programme: neurological disorders therapeutics - Herantis Pharma
Alternative Names: MANF - Herantis Pharma; Mesencephalic astrocyte-derived neurotrophic factor - Herantis PharmaLatest Information Update: 28 Nov 2021
Price :
$50 *
At a glance
- Originator Herantis Pharma
- Class Neuroprotectants
- Mechanism of Action Nerve growth factor receptor modulators; Neuron modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Neurological disorders
Highest Development Phases
- No development reported Neurological disorders
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for research development in Neurological-disorders in Finland
- 29 Aug 2018 Research programme: neurological disorders therapeutics - Herantis Pharma is available for licensing as of 29 Aug 2018.
- 12 Oct 2017 Early research in Neurological disorders in Finland (unspecified route) (Herantis pipleine, October 2017)